Search
Zongertinib
go.drugbank.com/drugs/DB18762ApprovedInvestigational[L53873,A274363] It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pathways while sparing wild-type epidermal growth factor receptor (EGFR), which … Zongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSunvozertinib
go.drugbank.com/drugs/DB18925InvestigationalSunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. … A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, P-glycoprotein inhibitorsSuzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigationalSuzetrigine is a NaV1.8 voltage-gated sodium channel blocker with analgesic properties NaV1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain signal transmission, making it a desirable therapeutic target for t...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 InducersOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesBaxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalBaxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLanepitant
go.drugbank.com/drugs/DB19599ExperimentalThe usage of the INN stem '-pitant' in the name indicates that Lanepitant is a neurokinin NK1 (substance P) receptor antagonist. Lanepitant has a monoisotopic molecular weight of 559.35 Da.
Categories: Neurokinin-1 Receptor AntagonistsFosfluconazole
go.drugbank.com/drugs/DB19833ExperimentalFosfluconazole is a small molecule drug. Fosfluconazole has a monoisotopic molecular weight of 386.07 Da.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsDitekiren
go.drugbank.com/drugs/DB19992ExperimentalDitekiren is a small molecule drug. The usage of the INN stem '-kiren' in the name indicates that Ditekiren is a renin inhibitor. Ditekiren has a monoisotopic molecular weight of 929.57 Da.
Categories: P-glycoprotein substratesLascufloxacin
go.drugbank.com/drugs/DB20002ExperimentalLascufloxacin is a small molecule drug. The usage of the INN stem '-oxacin' in the name indicates that Lascufloxacin is a nalidixic acid derivative antibacterial. Lascufloxacin has a monoisotopic molecular weight of 439.17 Da.
Categories: P-glycoprotein substratesCilobradine
go.drugbank.com/drugs/DB20039InvestigationalCilobradine is under investigation in clinical trial NCT02264041 (Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine).